Evidence map›Paper›PMID 26343846›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2015

Drug delivery, cell-based therapies, and tissue engineering approaches for spinal cord injury.

Shushi Kabu, Yue Gao, Brian K Kwon, Vinod Labhasetwar

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 2 pooled it
8.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 2 syntheses or guidelines pooled it, 184 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Local delivery of EGFRBioactive materials · 2024
    Article
  15. Article
  16. Article
  17. Review
  18. Histopathological and immunohistochemical investigation of the effect of Shilajit in rats with experimental spinal cord injury.Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2023
    Article
  19. Review
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Shushi KabuDepartment of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Yue GaoDepartment of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Brian K KwonDepartment of Orthopaedics, International Collaboration on Repair Discoveries (ICORD), University of British Columbia, Vancouver, BC, Canada V5Z 1M9.
Vinod LabhasetwarDepartment of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Electronic address: labhasv@ccf.org.
Cleveland Clinic Lerner College of Medicine · USInternational Collaboration On Repair Discoveries · CA

Funding

Antigen Loaded Particles for Tolerance InductionR01EB013198 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MILLER, STEPHEN D, SHEA, LONNIE D · 2011 to 2018
$4.1M
Neuronal Protective Nanoparticles for Treating Acute SCIR01NS092033 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI LABHASETWAR, VINOD D · 2015 to 2019
$2.2M
NIBIB NIH HHS R01EB013198NINDS NIH HHS R01 NS092033
6 · The paper itself

Abstract

Spinal cord injury (SCI) results in devastating neurological and pathological consequences, causing major dysfunction to the motor, sensory, and autonomic systems. The primary traumatic injury to the spinal cord triggers a cascade of acute and chronic degenerative events, leading to further secondary injury. Many therapeutic strategies have been developed to potentially intervene in these progressive neurodegenerative events and minimize secondary damage to the spinal cord. Additionally, significant efforts have been directed toward regenerative therapies that may facilitate neuronal repair and establish connectivity across the injury site. Despite the promise that these approaches have shown in preclinical animal models of SCI, challenges with respect to successful clinical translation still remain. The factors that could have contributed to failure include important biologic and physiologic differences between the preclinical models and the human condition, study designs that do not mirror clinical reality, discrepancies in dosing and the timing of therapeutic interventions, and dose-limiting toxicity. With a better understanding of the pathobiology of events following acute SCI, developing integrated approaches aimed at preventing secondary damage and also facilitating neuroregenerative recovery is possible and hopefully will lead to effective treatments for this devastating injury. The focus of this review is to highlight the progress that has been made in drug therapies and delivery systems, and also cell-based and tissue engineering approaches for SCI.

Indexed as

AnimalsCell- and Tissue-Based TherapyDrug Delivery SystemsGenetic TherapyHumansSpinal Cord InjuriesTissue EngineeringCNS injuryDrug therapyGene therapyGrowth factorsInflammationPolymersScaffold

Identifiers

PMID26343846
PMCPMC4656085
OpenAlexW1577089616

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.